@article{TLCR23547,
author = {Bryan C. Ulrich and Nicolas Guibert},
title = {Immunotherapy efficacy and gender: discovery in precision medicine},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {Suppl 3},
year = {2018},
keywords = {},
abstract = {Immunotherapy is transforming the care of cancer. In the past five years, checkpoint blockade agents targeting the PD-1/PD-L1 checkpoint (e.g., nivolumab, pembrolizumab) have garnered FDA approvals in diverse indications including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and more (1-5). While these agents produce durable responses for some patients, the science of identifying responders remains inexact; further work is needed to identify biomarkers which better predict patient response than current clinical practice.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/23547}
}